What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase. Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria,…”In the company’s words, NCT04250922 on ClinicalTrials.gov
- Tested for
- Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma, Solid Tumor, Unspecified, Child
- Main trialPhase 2/3
- “The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.”In the company’s words, NCT04250922 on ClinicalTrials.gov
Other drugs for Primary Glioblastoma
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- DordaviproneJazz Pharmaceuticals · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 15 Jan 2026 | LAM561 With RT and TMZ for Adults With Glioblastoma | |
| Phase 1/2Recruiting | Oct 2026 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | |
| Phase 1/2Completed | Sep 2016 | A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours | |
| Phase 1Completed | 1 Jul 2020 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026